A translational journey in Germany: From literature to local implementation of [89Zr]Zr-DFO-trastuzumab
Nuklearmedizin - NuclearMedicine · 01.08.2026 · 65 (04) · 265-270
DOI: 10.1055/a-2883-7600 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.08.2026. Verfasst von Joana do Mar Ferreira Machado und 11 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Tumor Diseases Dresden, Department of Translational Imaging in Oncology, Germany, Dresden. Hauptthemen laut MEDLINE: Zirconium, Trastuzumab, Radioisotopes, Radiopharmaceuticals.
Abstract (Originalsprache)
Aim [⁸⁹Zr]Zr-DFO-trastuzumab has emerged as a powerful tool to visualise non-invasively HER2 expression across metastatic lesions, complementing conventional pathological HER2 evaluation and helping to identify patients unlikely to benefit from therapy with trastuzumab-based therapies. This paper outlines the roadmap of the manufacturing implementation of [89Zr]Zr-DFO-trastuzumab at our centre in Germany.
Methods
In this paper, we describe the key questions encountered during implementation of the manufacturing process for [89Zr]Zr-DFO-trastuzumab and how these were addressed through discussions between academia, hospital departments, teams experienced in the radiolabelling of antibodies and regulatory authorities.
Results
Discussions with multiple institutions were essential for the implementation of the GMP-compliant radiosynthesis of [⁸⁹Zr]Zr-DFO-trastuzumab at our manufacturing site. Example decisions included shortening the shelf-life of [⁸⁹Zr]Zr-DFO-trastuzumab to 24 hours to mitigate container-closure integrity concerns and adoption of a bead-based method to determine the immunoreactive fraction.
Conclusion
This work presents a practical overview of operational considerations relevant to the clinical implementation of [⁸⁹Zr]Zr-DFO-trastuzumab, with potential applicability to other ⁸⁹Zr-labelled high-molecular-weight radiotracers in Germany. By sharing these practical insights, we aim to support broader patient access to established radiopharmaceuticals and encourage dialogue around open regulatory and practical questions, particularly in anticipation of future clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Center for Tumor Diseases Dresden, Department of Translational Imaging in Oncology, Germany, Dresden.
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Germany, Dresden.
- University Hospital Carl Gustav Carus, Department of Nuclear Medicine, Germany, Dresden.
- University Hospital Carl Gustav Carus, Department of Gynaecology and Obstetrics, Germany, Dresden.
- TU Dresden, Faculty of Chemistry and Food Chemistry, School of Science, Germany, Dresden.
ORCID-Profile: Joana do Mar Ferreira Machado
Zitieren
APA
Ferreira Machado, J. D. M., Zarschler, K., Knieß, T., Kreller, M., Miederer, M., Brandt, F., Apolle, R., Link, T., Winzer, R., Wimberger, P., Kopka, K., & Kiß, O. (2026). A translational journey in Germany: From literature to local implementation of [89Zr]Zr-DFO-trastuzumab. Nuklearmedizin - NuclearMedicine, 65(04), 265-270. https://doi.org/10.1055/a-2883-7600
Vancouver
Ferreira Machado JDM, Zarschler K, Knieß T, Kreller M, Miederer M, Brandt F, et al. A translational journey in Germany: From literature to local implementation of [89Zr]Zr-DFO-trastuzumab. Nuklearmedizin - NuclearMedicine. 2026;65(04):265-270. doi:10.1055/a-2883-7600
BibTeX
@article{FerreiraMachado2026,
author = {Ferreira Machado, Joana do Mar and Zarschler, Kristof and Knieß, Torsten and Kreller, Martin and Miederer, Matthias and Brandt, Florian and Apolle, Rudi and Link, Theresa and Winzer, Robert and Wimberger, Pauline and Kopka, Klaus and Kiß, Oliver},
title = {A translational journey in Germany: From literature to local implementation of [89Zr]Zr-DFO-trastuzumab},
journal = {Nuklearmedizin - NuclearMedicine},
year = {2026},
volume = {65},
number = {04},
pages = {265--270},
doi = {10.1055/a-2883-7600}
}
EUVIMED